Sunridge International's CEO, G. Richard Smith said, "the company was especially pleased to be entering the Indian market. We are introducing our PNT equipment and treatment in a number of markets around the world but India is a very special place, which we feel, offers enormous opportunity for us. Together with New Amsterdam, we look forward to helping, perhaps, literally millions of people suffering from glaucoma and ocular hypertension throughout India. We feel that our patented Pneumatic Trabeculoplasty (PNT) treatment can be a huge help."
PNT is a two-minute, non-invasive, cost effective treatment that only needs to be performed 3-4 times a year, allowing rural areas a treatment regime that might not otherwise be available to them. "Often in these rural locations, among very poor people, glaucoma is simply left untreated. For many, the cost of ongoing treatment is simply out of their reach. We feel that PNT provides an answer to these problems and gives people a chance to experience a safe, effective and affordable treatment. We shall be giving New Amsterdam audiences our fullest support and look forward to a long and mutually rewarding association with them."
Glaucoma is the second leading cause of blindness, affecting over 70 million people worldwide. PNT has been proven (through studies completed over the last 10 yrs) to be a safe, effective, non-invasive and a cost effective alternative for treatment for glaucoma and ocular hypertension. The 2-minute treatment has been developed, patented, and distributed by Sunridge International, wholly owned subsidiary, Ophthalmic International (www.oi-pnt.com).
For full details of PNT and its application, we invite you to visit Sunridge International's website at www.sunridgeint.com.